| pubmed-article:10903412 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10903412 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10903412 | lifeskim:mentions | umls-concept:C0080103 | lld:lifeskim |
| pubmed-article:10903412 | lifeskim:mentions | umls-concept:C0036341 | lld:lifeskim |
| pubmed-article:10903412 | lifeskim:mentions | umls-concept:C0040615 | lld:lifeskim |
| pubmed-article:10903412 | lifeskim:mentions | umls-concept:C0376558 | lld:lifeskim |
| pubmed-article:10903412 | lifeskim:mentions | umls-concept:C1704686 | lld:lifeskim |
| pubmed-article:10903412 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:10903412 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10903412 | pubmed:dateCreated | 2000-9-21 | lld:pubmed |
| pubmed-article:10903412 | pubmed:abstractText | There is evidence that the stage of illness at which antipsychotic treatment is initiated in schizophrenia may have consequences for its subsequent course. How this might relate to impaired adaptive life functioning in the long-term is poorly understood. | lld:pubmed |
| pubmed-article:10903412 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10903412 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10903412 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10903412 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10903412 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10903412 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10903412 | pubmed:issn | 0006-3223 | lld:pubmed |
| pubmed-article:10903412 | pubmed:author | pubmed-author:QuinnJJ | lld:pubmed |
| pubmed-article:10903412 | pubmed:author | pubmed-author:WaddingtonJ... | lld:pubmed |
| pubmed-article:10903412 | pubmed:author | pubmed-author:LamyLL | lld:pubmed |
| pubmed-article:10903412 | pubmed:author | pubmed-author:MoranMM | lld:pubmed |
| pubmed-article:10903412 | pubmed:author | pubmed-author:KinsellaAA | lld:pubmed |
| pubmed-article:10903412 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10903412 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:10903412 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:10903412 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10903412 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10903412 | pubmed:pagination | 163-6 | lld:pubmed |
| pubmed-article:10903412 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:meshHeading | pubmed-meshheading:10903412... | lld:pubmed |
| pubmed-article:10903412 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10903412 | pubmed:articleTitle | Long-term adaptive life functioning in relation to initiation of treatment with antipsychotics over the lifetime trajectory of schizophrenia. | lld:pubmed |
| pubmed-article:10903412 | pubmed:affiliation | Stanley Foundation Research Unit, St. Davnet's Hospital, Monaghan, Ireland. | lld:pubmed |
| pubmed-article:10903412 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10903412 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
